Nanoism: The Emergence of a New Medical Field in Preventive Medicine

Author: Tess Fries
Affiliation: Founder of Nanoism and Inventor of Elixira – AI-Guided Nanomedicine Platform for Cancer Prevention
Contact: contact@elixira.tech
Date: August 2025
DOI: https://doi.org/10.5281/zenodo.16990051

Abstract

This paper introduces Nanoism™, a new medical paradigm emerging from the unified integration of previously separate academic fields: nanoscale interventions, artificial intelligence, autonomy, and preventive medicine. Unlike traditional nanomedicine—which primarily augments diagnostics or therapeutics within existing care pathways—Nanoism establishes a field that complements and extends those pathways with proactive, always-on prevention, closed-loop control, and lifecycle outcomes. Elixira, a patent-pending, AI-guided, autonomous nanomedicine platform designed for lifelong cancer prevention across all cancer types, is presented as the first complete realization of this paradigm. Elixira transcends and evolves existing oncology models, and Nanoism is positioned as a natural evolution that can expand opportunities for patient benefit, sustainable industry growth, and long-term value creation. This paper presents Nanoism by describing what it is, what defines it as a distinct discipline, what makes it unique, why it is necessary for the future of medicine, and why it represents a promising new field shaping the future of healthcare.

Keywords: Nanoism, Paradigm, Elixira, Tess Fries, Nanobot, Nanomedicine, Nanotechnology, Cancer, Cancer Prevention, Artificial Intelligence, AI, Nanorobotics, Self-Powered Systems, Biotechnology, Autonomous Systems, Health Economics, Life Science, Medical Device, Healthcare, Health, Oncology, Innovation, Healthcare Innovation, Startup, Preventive Medicine, Future Medicine, Transhumanism, Technology, White Paper, Public Disclosure, Prior Art, Medtech, Deeptech, Ethics

1. Introduction

Healthcare today is largely structured around the detection and treatment of disease once symptoms have appeared. Oncology illustrates both the remarkable progress of modern medicine and the ongoing challenge of achieving durable cures and equitable access. At the same time, emerging technologies—such as nanoscale engineering, artificial intelligence, and autonomous systems—have advanced significantly in recent years, laying the foundation for future breakthrough applications in continuous, proactive, and autonomous approaches to preventive medicine. Together, these remarkable advances point toward an unprecedented opportunity to unify these separate fields into a framework greater than the sum of its parts.

Nanoism is the name and structure for this new field, and the patent-pending AI-guided autonomous nanomedicine platform Elixira is introduced as its first system-level instantiation for lifelong cancer prevention.

This paper aims to present Nanoism as a distinct discipline by integrating nanotechnology, artificial intelligence, autonomy, and prevention, and to show how it represents both the beginning of preventive medicine as a paradigm in future healthcare and a new growth frontier for the cancer industry.

2. Background: From Reactive to Proactive Medicine

Medical progress has advanced from symptomatic treatment to earlier detection, yet most infrastructures still operate within a visit-based, intervention-triggered model. This structure is reinforced by financial systems that reward treatment after disease has appeared rather than prevention before it arises. As a result, healthcare markets are largely built around serving the sick, while prevention—though increasingly recognized as essential—has historically lacked strong structural and economic support.

Recent advances in artificial intelligence and nanoscale engineering now make it possible to imagine a different path: nanoscale interfaces can intervene where disease originates, AI enables continuous sensing–decision–action loops, and autonomous systems reduce reliance on frequent clinical visits. What is needed is a framework that unifies these advances into a coherent approach to prevention.

Nanoism provides this framework. It shifts the objective from solely treating disease to protecting health by removing the risk of disease before it emerges. In doing so, Nanoism not only improves population health but also expands the market from treating a fraction of the population to protecting everyone. This creates strong incentives for a global transition toward preventive medicine—aligning improved health outcomes with sustainable growth opportunities for industry stakeholders, while reducing long-term costs for healthcare systems and society as a whole.

3. Defining Nanoism

Nanoism is defined as a medical field characterized by the following four pillars and operational criteria, distinguishing it from both conventional medicine and traditional nanomedicine.

3.1 Pillars

Nanoism is defined as a medical field characterized by four foundational pillars that distinguish it from both conventional medicine and traditional nanomedicine:

1. Nanoscale Intervention: Operations at cellular and subcellular scales with targeted interaction at or near the origin of pathology.

2. AI-Guided Autonomy: Embedded intelligence that executes real-time, closed-loop decisions within pre-specified safety bounds.

3. Prevention-First Orientation: The primary objective is to suppress risk and neutralize pathology before symptoms manifest, while retaining curative capabilities when required.

4. Self-Sufficient Symbiosis: Systems must operate in long-term symbiosis with the body, remaining fully autonomous and self-sustaining through internal energy-harvesting and adaptive regulation, minimizing dependence on continuous external inputs or repeated treatments.

3.2 Inclusion Criteria (all required)

- (C1) Scale & Specificity: Action at cellular/molecular level with disease-relevant precision.

- (C2) Closed-Loop Control: Continuous sensing linked to autonomous decision-making and verifiable actions.

- (C3) Preventive Efficacy Goal: Clinical endpoints prioritize prevention (reduced incidence, delayed onset, recurrence suppression).

- (C4) Long-Horizon Operation: Durability and safe oversight across years, with defined update processes.

- (C5) Ethical & Safety Governance: Multilayer safeguards, human override, transparency, and patient-centric consent.

- (C6) Symbiosis with the Body: Technologies must function in continuous interaction with the body, adapting dynamically to physiological changes rather than operating as isolated or episodic interventions.

- (C7) Self-Sustaining Autonomy: Systems must be fully autonomous and capable of maintaining operation through self-energy or internal energy-harvesting mechanisms, eliminating reliance on continuous external inputs or repeated treatments.

3.3 Exclusion Notes

Projects that solely diagnose without autonomous preventive action, or rely exclusively on episodic drug dosing without closed-loop integration, remain within nanomedicine or digital health rather than Nanoism. Similarly, technologies that act only as external tools or one-time delivery systems without establishing continuous symbiosis with the body do not qualify as Nanoism.

4. Why a New Field Is Necessary and Beneficial

Uniqueness: Nanoism unites previously separate fields into a coherent paradigm that creates something greater than the sum of its parts: a structured discipline of preventive nanomedicine. By integrating nanoscale access, AI-guided autonomy, and prevention-first economics, it establishes preventive medicine as a structured discipline not captured within existing fields.

Necessity: With the global cancer burden rising and associated healthcare and societal costs continuing to increase, current approaches point toward the opportunity for a new paradigm in preventive medicine. To be effective, interventions must target earlier and subtler stages of pathogenesis. A new framework is therefore required—one that shifts focus from episodic treatment toward continuous prevention—making Nanoism a necessary foundation for the future of medicine.

Benefits:

- **Clinical:** Earlier neutralization of malignant processes; potential reduction in morbidity and treatment intensity.

- **Systemic:** Fewer acute episodes, smoother healthcare utilization, and increased resilience.

- **Economic:** By adding prevention as a new business domain, Nanoism expands oncology markets from treating only the sick to protecting the health of entire populations. Preventive subscriptions, lifecycle servicing, and outcome-aligned contracts can complement existing revenue models, creating new opportunities for growth while simultaneously delivering improved health outcomes.

5. Case Study: Elixira as the First Realization of Nanoism

5.1 Purpose and Concept

Elixira is a patent-pending, AI-guided, autonomous nanomedicine platform intended for one-time injection to enable lifelong cancer prevention. It exemplifies Nanoism's pillars by operating near oncogenesis origins, linking sensing to action in closed loop, and prioritizing prevention while aligning with industry growth pathways.

5.2 Architectural Principles (non-sensitive overview)

Elixira's architecture reflects four integrated design logics:

1. **Autonomous Core Design**
   The nanobot system is built as a fully integrated artificial immune unit, capable of detecting, classifying, and neutralizing malignant cells with high precision, while minimizing impact on healthy tissue.

2. **Hybrid Energy and Self-Sufficiency**
   The platform is designed for sustained, independent operation over long horizons, ensuring continuous function without reliance on frequent external inputs.

3. **Closed-Loop Intelligence with Safety Layers**
   An advanced AI processor governs sensing, decision, and action in real time. The architecture is designed with multiple protective layers, including internal isolation, built-in safeguards, auditable transparency, and fail-safe mechanisms to ensure reliability and trust.

4. **Symbiotic Operation and Lifecycle Durability**
   The system is designed for long-term compatibility with the human body, emphasizing sustained operation, adaptability to physiological changes, and compatibility with existing clinical monitoring methods.

5.3 Economic Alignment

Elixira supports the evolution of oncology toward prevention-driven healthcare economics. By expanding the scope from treatment of illness to protection of health, Elixira enables new value pathways for industry stakeholders. Elixira complements existing therapies by establishing a prevention sector that strengthens healthcare resilience while creating opportunities for sustainable growth.

6. Ethical, Safety, and Governance Considerations

Nanoism is defined by a commitment to ethics and safety at its core. Systems within the field must operate in long-term symbiosis with the human body, remain secure against external interference, and be developed with patient rights and ethical responsibility as guiding principles. These safeguards ensure that preventive nanomedicine not only protects health but also strengthens trust in healthcare and the industries that support it.

7. Limitations and Scope

This paper is conceptual and omits sensitive intellectual property. While Elixira is presented as a motivating case, it is based on existing scientific advances and a patent-pending system. Specific technical mechanisms, materials, and control policies are intentionally withheld to protect intellectual property.

8. Conclusion

Nanoism is a new field that integrates nanoscale access, AI-guided autonomy, prevention-first objectives, and lifecycle sustainability into preventive medicine approaches. Elixira serves as the first example of this paradigm, demonstrating that such systems can be realized in ways that are highly compatible with and beneficial to healthcare. Nanoism represents an evolutionary step that allows medicine to expand from treatment into prevention, aligning clinical progress with sustainable healthcare economics. Today's scientific advances enable methods that will define the future of healthcare not by managing disease, but by preventing it altogether—with healthcare systems and industry as key partners in enabling that transformation.

References

Beauchamp, T. L., & Childress, J. F. (2019). *Principles of biomedical ethics* (8th ed.). Oxford University Press.

Ekwueme, D. U., Halpern, M. T., Chesson, H. W., Ashok, M., Drope, J., Hong, Y.-R., Maciosek, M., Pesko, M. F., & Kenkel, D. S. (2022). Health economics research in primary prevention of cancer: Assessment, current challenges, and future directions. *JNCI Monographs, 2022*(59), 28–41. https://doi.org/10.1093/jncimonographs/lgac014

Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. *Nanomedicine: Nanotechnology, Biology and Medicine, 9*(1), 1–14. https://doi.org/10.1016/j.nano.2012.05.013

Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., ... & Dean, J. (2019). A guide to deep learning in healthcare. *Nature Medicine, 25*(1), 24–29. https://doi.org/10.1038/s41591-018-0316-z

Mittelstadt, B. D. (2019). Principles alone cannot guarantee ethical AI. *Nature Machine Intelligence, 1*(11), 501–507. https://doi.org/10.1038/s42256-019-0114-4

Ratushnyak, S., Hoogendoorn, M., & van Baal, P. H. M. (2019). Cost-effectiveness of cancer screening: Health and costs in life years gained. *American Journal of Preventive Medicine, 57*(6), 792–799. https://doi.org/10.1016/j.amepre.2019.07.027

Shih, Y.-T., Sabik, L. M., Stout, N. K., Halpern, M. T., Lipscomb, J., Ramsey, S., & Ritzwoller, D. P. (2022). Health economics research in cancer screening: Research opportunities, challenges, and future directions. *JNCI Monographs, 2022*(59), 42–50. https://doi.org/10.1093/jncimonographs/lgac008

Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015). Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. *Journal of Controlled Release, 200,* 138–157. https://doi.org/10.1016/j.jconrel.2014.12.030

Author Note

This manuscript is conceptual and omits sensitive intellectual property by design. All descriptions of Elixira are intentionally high-level and non-enabling; specific algorithms, materials, and control policies are not disclosed. Nanoism is presented not only as a technical framework, but as the beginning of a new discipline in medicine—one that elevates healthcare from reactive to proactive. Its aim is to shift the trajectory of global health from managing disease after it erupts to protecting health before disease ever gets hold.